{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:16:30Z","timestamp":1793834190670,"version":"4.6.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":864,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure in adults is characterized by reduction of long-chain fatty acid oxidation in favour of carbohydrate metabolism. This adaptive phenomenon becomes maladaptive because energy conversion decreases and lipid toxic derivatives known to impair cardiac function are accumulating. No data are available concerning metabolic modification in heart failure in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In order to evaluate the fatty acid oxidation in children suffering from heart failure, acylcarnitine profiles on dried blood spots were obtained from children under 16 years old with dilated cardiomyopathy and clinical heart failure (DCM-HF) and control children. Nine children were included in the DCM-HF group and eight in the control group. Acylcarnitine profiles revealed a significant 3.1-fold increase of total acylcarnitines (sum of C3 to C18 acylcarnitine species) in DCM-HF children compared with controls. This result persisted considering the sum of long-chain acylcarnitines (sum of C14 to C18 species), medium-chain acylcarnitines (sum of C8 to C12 species), and short-chain acylcarnitines (sum of C3 to C6 species), respectively, 2.0-, 2.6-, and 1.9-fold increase compared with the control group. A significant linear correlation was found between left ventricular dilatation or ejection fraction and acylcarnitines accumulation. Finally, acylcarnitine ratio C16OH\/C16 and C18OH\/C18 enhanced in the DCM-HF group, suggesting a diminution of the long-chain hydroxyl acyl-CoA dehydrogenase activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest down-regulation of fatty acid oxidation in children with heart failure. Such lipidomic alteration could worsen heart function and may suggest considering a metabolic treatment of heart failure in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14449","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:44:15Z","timestamp":1692841455000},"page":"3114-3122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Increased Acylcarnitines in Infant Heart Failure Indicate Fatty Acid Oxidation Inhibition: Towards Therapeutic Options?"],"prefix":"10.1093","volume":"10","author":[{"given":"Jean","family":"Issa","sequence":"first","affiliation":[{"name":"Institut des Cardiopathies Cong\u00e9nitales de Tours, H\u00f4pital Gatien de Clocheville, CHU Tours , 49 Boulevard B\u00e9ranger, Tours, 37000 ,","place":["France"]},{"name":"Universit\u00e9 Fran\u00e7ois Rabelais , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lodewyckx","sequence":"additional","affiliation":[{"name":"Institut des Cardiopathies Cong\u00e9nitales de Tours, H\u00f4pital Gatien de Clocheville, CHU Tours , 49 Boulevard B\u00e9ranger, Tours, 37000 ,","place":["France"]},{"name":"Universit\u00e9 Fran\u00e7ois Rabelais , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Blasco","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Fran\u00e7ois Rabelais , Tours ,","place":["France"]},{"name":"Service de Biochimie et Biologie Mol\u00e9culaire, CHU Tours , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Benz-de-Bretagne","sequence":"additional","affiliation":[{"name":"Service de Biochimie et Biologie Mol\u00e9culaire, CHU Tours , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Labarthe","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Fran\u00e7ois Rabelais , Tours ,","place":["France"]},{"name":"D\u00e9partement de P\u00e9diatrie, CHU de Tours , Tours ,","place":["France"]},{"name":"INSERM UMR 1069 , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-7544","authenticated-orcid":false,"given":"Bruno","family":"Lefort","sequence":"additional","affiliation":[{"name":"Institut des Cardiopathies Cong\u00e9nitales de Tours, H\u00f4pital Gatien de Clocheville, CHU Tours , 49 Boulevard B\u00e9ranger, Tours, 37000 ,","place":["France"]},{"name":"Universit\u00e9 Fran\u00e7ois Rabelais , Tours ,","place":["France"]},{"name":"INSERM UMR 1069 , Tours ,","place":["France"]},{"name":"FHU PreciCare , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"2026012113210945500_ehf214449-bib-0001","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/CIRCHEARTFAILURE.108.820217","article-title":"Heart failure in children: part I: history, etiology, and pathophysiology","volume":"2","author":"Hsu","year":"2009","journal-title":"Circ Heart Fail"},{"key":"2026012113210945500_ehf214449-bib-0002","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1161\/01.CIR.96.7.2190","article-title":"Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy","volume":"96","author":"Neubauer","year":"1997","journal-title":"Circulation"},{"key":"2026012113210945500_ehf214449-bib-0003","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"2026012113210945500_ehf214449-bib-0004","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/01.CIR.94.11.2837","article-title":"Fatty acid oxidation enzyme gene expression is downregulated in the failing heart","volume":"94","author":"Sack","year":"1996","journal-title":"Circulation"},{"key":"2026012113210945500_ehf214449-bib-0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00019501-199602000-00004","article-title":"Abnormal mechanical function in diabetes: relationship to altered myocardial carbohydrate\/lipid metabolism","volume":"7","author":"Lopaschuk","year":"1996","journal-title":"Coron Artery Dis"},{"key":"2026012113210945500_ehf214449-bib-0006","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bbamcr.2012.08.014","article-title":"Targeting mitochondrial oxidative metabolism as an approach to treat heart failure","volume":"1833","author":"Fillmore","year":"2013","journal-title":"Biochim Biophys Acta BBA - Mol Cell Res"},{"key":"2026012113210945500_ehf214449-bib-0007","doi-asserted-by":"crossref","first-page":"H768","DOI":"10.1152\/ajpheart.00820.2016","article-title":"Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond","volume":"313","author":"Ruiz","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012113210945500_ehf214449-bib-0008","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF01799385","article-title":"Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism","volume":"13","author":"Millington","year":"1990","journal-title":"J Inherit Metab Dis"},{"key":"2026012113210945500_ehf214449-bib-0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpba.2017.10.013","article-title":"The combination of four analytical methods to explore skeletal muscle metabolomics: better coverage of metabolic pathways or a marketing argument?","volume":"148","author":"Bruno","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"2026012113210945500_ehf214449-bib-0010","first-page":"63","article-title":"Four years' experience in the diagnosis of very long-chain acyl-CoA dehydrogenase deficiency in infants detected in three Spanish newborn screening centers","volume":"39","author":"Merinero","year":"2018","journal-title":"JIMD Rep"},{"key":"2026012113210945500_ehf214449-bib-0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003190","article-title":"Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure","volume":"5","author":"Hunter","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026012113210945500_ehf214449-bib-0012","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jacc.2015.02.018","article-title":"Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure","volume":"65","author":"Cheng","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026012113210945500_ehf214449-bib-0013","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2015.10.079","article-title":"Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support","volume":"67","author":"Ahmad","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012113210945500_ehf214449-bib-0014","article-title":"Outcomes and genotype correlations in patients with mitochondrial trifunctional protein or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency enrolled in the IBEM-IS database","volume":"32","author":"Lim","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"2026012113210945500_ehf214449-bib-0015","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ehf2.13233","article-title":"Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome","volume":"8","author":"van der Meulen","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012113210945500_ehf214449-bib-0016","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bbadis.2017.04.005","article-title":"Pharmacological inhibition of carnitine palmitoyltransferase 1 restores mitochondrial oxidative phosphorylation in human trifunctional protein deficient fibroblasts","volume":"1863","author":"Lefort","year":"2017","journal-title":"Biochim Biophys Acta BBA - Mol Basis Dis"},{"key":"2026012113210945500_ehf214449-bib-0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041686","article-title":"Long-chain acylcarnitines regulate the hERG channel. Obukhov AG, \u00e9diteur","volume":"7","author":"Ferro","year":"2012","journal-title":"PLoS ONE"},{"key":"2026012113210945500_ehf214449-bib-0018","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00005344-200007000-00002","article-title":"Long-chain acylcarnitine induces Ca2+ efflux from the sarcoplasmic reticulum","volume":"36","author":"Yamada","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012113210945500_ehf214449-bib-0019","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrendo.2015.129","article-title":"Acylcarnitines\u2014old actors auditioning for new roles in metabolic physiology","volume":"11","author":"McCoin","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"2026012113210945500_ehf214449-bib-0020","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","article-title":"Ceramide is a cardiotoxin in lipotoxic cardiomyopathy","volume":"49","author":"Park","year":"2008","journal-title":"J Lipid Res"},{"key":"2026012113210945500_ehf214449-bib-0021","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1021\/acs.jproteome.8b00270","article-title":"Comprehensive and reproducible untargeted lipidomic workflow using LC-QTOF validated for human plasma analysis","volume":"17","author":"Forest","year":"2018","journal-title":"J Proteome Res"},{"key":"2026012113210945500_ehf214449-bib-0022","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cvr\/cvr038","article-title":"Modulating fatty acid oxidation in heart failure","volume":"90","author":"Lionetti","year":"2011","journal-title":"Cardiovasc Res"},{"key":"2026012113210945500_ehf214449-bib-0023","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1161\/01.RES.0000086964.07404.A5","article-title":"Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase","volume":"93","author":"Lopaschuk","year":"2003","journal-title":"Circ Res"},{"key":"2026012113210945500_ehf214449-bib-0024","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/CS20060307","article-title":"A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study","volume":"113","author":"Holubarsch","year":"2007","journal-title":"Clin Sci"},{"key":"2026012113210945500_ehf214449-bib-0025","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"2026012113210945500_ehf214449-bib-0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/FTD.0000000000000237","article-title":"Can perhexiline be utilized without long-term toxicity? A clinical practice audit","volume":"38","author":"Phuong","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2026012113210945500_ehf214449-bib-0027","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1073\/pnas.0336724100","article-title":"A critical role for PPAR\u03b1-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content","volume":"100","author":"Finck","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026012113210945500_ehf214449-bib-0028","doi-asserted-by":"crossref","first-page":"H140","DOI":"10.1152\/ajpheart.00424.2006","article-title":"AMPK and metabolic adaptation by the heart to pressure overload","volume":"292","author":"Allard","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012113210945500_ehf214449-bib-0029","doi-asserted-by":"crossref","first-page":"H1425","DOI":"10.1152\/ajpheart.00722.2004","article-title":"Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid","volume":"288","author":"Labarthe","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026012113210945500_ehf214449-bib-0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymgme.2016.08.008","article-title":"Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders","volume":"119","author":"Vockley","year":"2016","journal-title":"Mol Genet Metab"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/3114\/66227858\/eschf_10_5_3114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/3114\/66227858\/eschf_10_5_3114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:25:54Z","timestamp":1769019954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/5\/3114\/8284389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,23]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14449","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"2023-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}